Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Gains from Sales and Divestitures (2022 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $380000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 19.97% to $380000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $380000.0 through Dec 2025, up 19.97% year-over-year, with the annual reading at $380000.0 for FY2025, 19.97% up from the prior year.
  • Gains from Sales and Divestitures hit $380000.0 in Q4 2025 for Protagonist Therapeutics, up from $75500.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $380000.0 in Q4 2025 to a low of $75500.0 in Q3 2025.
  • Historically, Gains from Sales and Divestitures has averaged $164335.3 across 4 years, with a median of $114000.0 in 2023.
  • Biggest five-year swings in Gains from Sales and Divestitures: increased 8.87% in 2023 and later soared 177.85% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $108462.0 in 2022, then increased by 5.11% to $114000.0 in 2023, then skyrocketed by 177.85% to $316748.0 in 2024, then grew by 19.97% to $380000.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for PTGX at $380000.0 in Q4 2025, $75500.0 in Q3 2025, and $316748.0 in Q4 2024.